Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 43 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Persistent endothelial dysfunction after glycaemic improvement: intervention timing and functional outcomes

  1. 1Department of Internal Medicine, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  2. 2Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
  3. 3Department of Endocrinology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Abstract

Endothelial dysfunction can persist after glycaemic improvement, but the evidence for its reversal depends on when treatment starts and which outcome is measured. This targeted narrative review compares experimental glucose-withdrawal studies, human vascular investigations and clinical follow-up reports by exposure, intervention timing, cellular source and endpoint. Persistent abnormalities involve inflammatory chromatin regulation, redox signalling, mitochondrial maintenance, DNA methylation and endothelial repair. Interventions started during glucose lowering improved arterial relaxation or reduced microvascular leakage in experimental models. Mitochondrial interventions improved organelle measurements without establishing vascular functional recovery. Evidence for treatment after a documented period of persistence is limited: selected studies measured repair behaviour, inflammatory responses or organ function, with unresolved timing or pretreatment-state limitations. These findings do not establish sustained reversal of an established endothelial deficit. Human studies report improvement in selected forearm and skin responses and acute glucagon-like peptide-1 responsiveness, alongside studies with no detectable improvement in flow-mediated dilation. A qualitative examination that sets aside reports with uncertain schedules or incomplete assessment retains support for endpoint-specific modifiability during glucose lowering; the evidence for delayed reversal remains limited. Endocrine, mitochondrial and vascular observations from separate settings do not establish a complete causal pathway. Sex representation and donor replication further constrain generalisation. Recovery studies should document the pretreatment deficit under stable, improved glycaemia, pair molecular and vascular measurements, and assess benefit during continued treatment and after withdrawal. Effects on clinical events require separate evaluation.

Related

  1. 1085 Educational intervention to increase utilization of ICD-10 codes for immune-related adverse events: a quality improvement initiative
    Aliyah Pabani, Asha E Kodan
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textImmunologyOncologyDOAJ
  2. Research on the impact of generative AI interaction modes on the improvement of school-age children’s early reading ability and college students’ auxiliary intervention
    Yanjiao Dong, Guoyan Li
    Frontiers in public healthPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC
  3. Improving Awareness of Oman Medical Specialty Board Training Bylaws Among First-Year Pediatric Residents Using a Flipped Classroom Intervention: A Quality Improvement Project
    Saniya Al Husaini, Abdul Hamid Al Hinai, Majan Al Siyabi +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Immune Consequences of Endothelial Cells’ Activation and Dysfunction During Sepsis
    Stéphanie Pons, Marine Arnaud, Maud Loiselle +3
    Critical Care ClinicsPeer-reviewedLicence not stated75 citedEpidemiology & public healthHAL
  5. Sepsis-associated endothelial dysfunction: clinical phenotypes, biomarkers, bedside evidence, and translational implications
    Song Qin, Ninan Dai, Fengyun Xu +2
    The Journal of clinical investigationPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{gu2026persistent,
  title = {{Persistent endothelial dysfunction after glycaemic improvement: intervention timing and functional outcomes}},
  author = {Yuan-ye Gu and Si-yu Qiao and Xiao-teng Feng and Duan Zhou and Lin Shen and Yan-yun Ma and Yi-hong Wei},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = nov,
  doi = {10.3389/fendo.2026.2030665},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.2030665/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Persistent endothelial dysfunction after glycaemic improvement: intervention timing and functional outcomes
AU  - Yuan-ye Gu
AU  - Si-yu Qiao
AU  - Xiao-teng Feng
AU  - Duan Zhou
AU  - Lin Shen
AU  - Yan-yun Ma
AU  - Yi-hong Wei
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.2030665
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.2030665/full
AB  - Endothelial dysfunction can persist after glycaemic improvement, but the evidence for its reversal depends on when treatment starts and which outcome is measured. This targeted narrative review compares experimental glucose-withdrawal studies, human vascular investigations and clinical follow-up reports by exposure, intervention timing, cellular source and endpoint. Persistent abnormalities involve inflammatory chromatin regulation, redox signalling, mitochondrial maintenance, DNA methylation and endothelial repair. Interventions started during glucose lowering improved arterial relaxation or reduced microvascular leakage in experimental models. Mitochondrial interventions improved organelle measurements without establishing vascular functional recovery. Evidence for treatment after a documented period of persistence is limited: selected studies measured repair behaviour, inflammatory responses or organ function, with unresolved timing or pretreatment-state limitations. These findings do not establish sustained reversal of an established endothelial deficit. Human studies report improvement in selected forearm and skin responses and acute glucagon-like peptide-1 responsiveness, alongside studies with no detectable improvement in flow-mediated dilation. A qualitative examination that sets aside reports with uncertain schedules or incomplete assessment retains support for endpoint-specific modifiability during glucose lowering; the evidence for delayed reversal remains limited. Endocrine, mitochondrial and vascular observations from separate settings do not establish a complete causal pathway. Sex representation and donor replication further constrain generalisation. Recovery studies should document the pretreatment deficit under stable, improved glycaemia, pair molecular and vascular measurements, and assess benefit during continued treatment and after withdrawal. Effects on clinical events require separate evaluation.
SN  - 1664-2392
ER  -